According to news from the investment community on January 11, following the completion of Series A financing of 100 million yuan in July 2021, Beijing Enze Kangtai Biotechnology Co., Ltd. has received good news again. Recently, the company announced the completion of Series A+ strategic financing , led by
Baidu Ventures
, with existing shareholders
Taiyu Investment and Volcano Capital
continuing to invest. The introduction of two rounds of blockbuster financing fully proves the capital market's recognition of Enze Kangtai's forward-looking strategic layout and continuous innovation capabilities in the exosomes track, and will also accelerate the company to become a new leading enterprise with first-mover advantages in the exosomes field.
In terms of exosome translational medical research, Enze Kangtai has spent more than four years continuously polishing and iterating exosome technology service products, forming a high-throughput multi-group enterprise with exosomes as its core competitiveness. It has a rich product line including scientific solutions and translational medical research solutions with exosome engineering transformation and mass production as its core competitiveness, involving more than 30 products and services.
Enze Kangtai mainly cooperates with clinical experts and biological companies to carry out scientific research. Currently, it has established cooperation with more than 100 well-known tertiary hospitals and scientific research institutions in China, and has achieved a series of important results: 80 SCI papers have been published He has applied for 16 invention patents, obtained 5 new technology and new product certifications in Beijing, participated in writing expert knowledge on exosomes, and co-organized exosomes research and application professional committee of the Chinese Association of Research Hospitals. The forum of the University of Physical Education. In the future, Enze Kangtai will continue to focus on the latest cutting-edge research on exosomes, develop in-depth underlying technologies, and continue to output optimal exosome technology service solutions.
Regarding this financing,
Enze Kangtai CEO Kong Guanyi
said: I am very grateful to the new and old shareholders for their recognition and support. Since its establishment four years ago, Enze Kangtai has always adhered to the corporate mission of biotechnology to promote medical development and benefit a better life. It is committed to exosome technology research and clinical transformation, and has built an exosome translational medicine platform with core competitiveness and independent intellectual property rights. exosome drug delivery platform and continue to promote the development of the industry. At present, the company mainly covers two business directions: translational medical research services based on exosomes and innovative drug research and development based on exosomes as carriers. The company has accumulated a stable core team, formed a data-driven and rapid iteration working method and the values ??of altruism, diligence, responsibility, trust, always loving, and embracing change, laying a solid foundation for the company's rapid future development. This round of financing will help the company build a higher-quality engineered exosome research and transformation platform.
Zhang Zihao, investment manager of Baidu Ventures
said: Exosomes are regarded as new clinical markers for various diseases such as tumors, and are also expected to become a new type of engineered drug delivery Carriers have become a hot research topic in recent years. Globally, engineered exosome pipelines have entered the early stages of clinical development. Enze Kangtai entered this track earlier in the country and has a pragmatic and professionally experienced talent team. It has now completed the construction of an engineered exosome innovation platform and the layout of core patented technologies, highlighting its industry position and advantages. It is hoped that the participation of Baidu Venture Capital can help the company promote the research and development of related products and jointly promote the development of the company and even this field.
Dr. Ji Tianrong, founder and general manager of Taiyu Investment
said: As a new drug delivery carrier, exosomes have good biocompatibility, low immunogenicity, and can pass through Biological barriers can be engineered and targeted and have great potential for future development. As the leading company in domestic exosome research and development, Enze Kangtai has in-depth research in bioinformatics, biochemistry and other aspects of its team, and maintains close cooperation with the exosome industry association, with a prominent industry position. Its exosome engineering platform can achieve external or internal loading of target proteins through scaffold proteins based on independent intellectual property rights, and can efficiently carry target protein fragments, nucleic acid sequences, etc., with the development of its Daxing GMP pilot plant. The launch will definitely promote the vigorous progress of its product pipeline and achieve early product launch.
This article is original from the investment community. When reprinting on the web, the source of the investment community and the author's name must be indicated at the beginning of the article. For reprinting on WeChat, please contact us for authorization in the original comment area of ??WeChat. Any illegal reprinting will be held accountable.